Antihemorrhagic - Thrombotargets Corp

Trombosis
TT 103MH

[ Cerrar ]

Discovery & Pipeline

Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms (), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.

Antihemorrhagic

We are developing the first antihemorrhagic drug useful for treating topically all kinds of bleeding. The most advanced drug candidate, TT-103MH, is a proprietary targeted antihemorrhagic human recombinant protein that induces a fast, efficient and stable blood coagulation.

TT 103MH

TT-103MH is a proprietary targeted antihemorrhagic human recombinant protein that induces a fast, efficient and stable blood coagulation.

Antihemorrhagic information

Novel and significantly radical approach for the treatment of bleeding disorders, using a topical formulation. See all antihemorrhagic information of new discover TT-103MH for bleeding disorders.

Hemostatic agents

The novel and most revolutionary hemostatic agents. Thrombotargets has developed the TT-103MH, the human recombinant antibleeding protein that has been designed to treat all kind of bleeding disorders

Thrombotargets is developing TT- 103MH, a novel and significantly radical approach for the treatment of bleeding disorders. Using a topical formulation TT-103MH, will be effective in treating:

• Healthy subjects
• Haemophilic patients
• Inherited and acquired coagulation and platelet disorders
• Haemorrhages induced by anticoagulant and antiplatelet drugs.